SCHEMBL1554501

SCHEMBL1554501

CN(C)/C=C(\C(=O)c1cccc(F)c1)c1ccc(Cl)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.50
KCNQ2 O43526 3/20 0.50
KCNE1 P15382 2/20 0.50
KCNQ1 P51787 2/20 0.50
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
KCNQ5 Q9NR82 1/20 0.41
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
NFE2L2 Q16236 2/20 0.38
BACE1 P56817 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12709030 1.00 KCNQ3 (0.50) KCNQ3KCNQ2KCNE1KCNQ1CES2
SCHEMBL1554502 1.00 KCNQ3 (0.50) KCNQ3KCNQ2KCNE1KCNQ1CES2
SCHEMBL1553299 0.85 CYP11B1 (0.50) KCNQ3KCNQ2CES2CES1CYP11B1
SCHEMBL1553298 0.85 CYP11B1 (0.50) KCNQ3KCNQ2CES2CES1CYP11B1
SCHEMBL12709046 0.85 CYP11B1 (0.50) KCNQ3KCNQ2CES2CES1CYP11B1
SCHEMBL5353609 0.79 CES2 (0.50) CES2CES1ALDH1A1TSHRSMN1; SMN2
SCHEMBL5353608 0.79 CES2 (0.50) CES2CES1ALDH1A1TSHRSMN1; SMN2
SCHEMBL23832211 0.76 NAPRT (0.54) KCNQ3KCNQ2KCNE1KCNQ1CYP11B1
SCHEMBL16460479 0.76 KCNQ3 (0.62) KCNQ3KCNQ2KCNE1KCNQ1CES2
SCHEMBL1554028 0.75 CACNA1B (0.44) CES2CES1CYP11B1CYP11B2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1439175-B1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2011-04-27 EP disclosed
EP-2246344-A1 Pyrimidine compounds and medicinal composition thereof Eisai R&D Management Co., Ltd. (JP) 2010-11-03 EP disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1439175-A1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF CBR3, AHR, HCCS KCNQ3 952/4885KCNQ2 1003/4885KCNE1 1197/4885
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof ADORA2B, ADORA2A, ADORA3 KCNQ3 2515/4885KCNQ2 2592/4885KCNE1 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.